Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, Alessandro D Santin, Emeline Colomba, David S Miller, Keiichi Fujiwara, Sandro Pignata, Sally Baron-Hay, Isabelle Ray-Coquard, Ronnie Shapira-Frommer, Kimio Ushijima, Jun Sakata, Kan Yonemori, Yong Man Kim, Eva M Guerra, Ulus A Sanli, Mary M McCormack, Alan D Smith, Stephen Keefe, Steven Bird, Lea Dutta, Robert J Orlowski, Domenica Lorusso
BACKGROUND: Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive either lenvatinib (20 mg, administered orally once daily) plus pembrolizumab (200 mg, administered intravenously every 3 weeks) or chemotherapy of the treating physician's choice (doxorubicin at 60 mg per square meter of body-surface area, administered intravenously every 3 weeks, or paclitaxel at 80 mg per square meter, administered intravenously weekly [with a cycle of 3 weeks on and 1 week off])...
February 3, 2022: New England Journal of Medicine